Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

JUPITER, Fla. — Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today highlighted continued progress across multiple global health collaborations that further validate the capabilities of its proprietary C1 protein production platform while supporting its broader commercialization strategy.

Dyadic’s C1 platform is designed to enable rapid, high-yield, and cost efficient production of recombinant proteins, vaccine antigens, monoclonal antibodies (mAbs), therapeutic proteins, enzymes, and other biologics. By accelerating strain development and efficiently secreting target proteins, C1 has the potential to address one of the industry’s most significant challenges: manufacturing biologics faster, at larger scale, and at lower cost.

The Company believes its fully funded emerging infectious disease preparedness initiatives, including programs targeting Ebola and hantavirus, are providing real-world demonstrations of C1’s potential advantages in rapid response. These collaborations are intended to showcase how C1 may accelerate the development and production of critical biologics when speed, flexibility, scalability and manufacturing efficiency are essential.

Dyadic’s Gates Foundation-supported research programs are evaluating the use of C1 for global health monoclonal antibody applications, including RSV and malaria. The Company has received the full $3.1 million Gates Foundation grant, including the final payment of $738,743 in June 2026, which is expected to fully fund the ongoing research.

To date, studies have shown that C1-produced monoclonal antibodies demonstrated binding and neutralization characteristics comparable to antibodies produced using traditional CHO cell systems. In addition, the C1 platform has demonstrated higher production yields at lower projected manufacturing costs, with multiple production runs completed during the timeframe typically required for a single CHO manufacturing cycle.

As part of CEPI’s 100 Days Mission and the $4.5 million CEPI/FBS/Dyadic collaboration, researchers have demonstrated plasmid-to-purified-protein production in approximately 15 days using the C1 platform. This milestone highlights the potential of C1 to significantly reduce development and manufacturing timelines for vaccine antigens and monoclonal antibodies, while supporting improved productivity and cost efficiency.

In Dyadic’s recently announced collaboration with Scripps Research focused on Bundibugyo Ebola preparedness, the Company is applying its rapid C1 workflow to produce complex viral antigens for evaluation in non-mRNA vaccine studies. Dyadic currently expects to deliver initial purified antigen samples to Scripps by the end of July 2026, providing an additional opportunity to demonstrate C1’s ability to support accelerated outbreak response efforts.

Dyadic’s participation in global preparedness initiatives, including initiatives involving the European Vaccines Hub and Fondazione Biotecnopolo di Siena, continues to expand awareness and validation of the C1 platform for high-priority infectious disease applications, including vaccine antigen and monoclonal antibody opportunities targeting Ebola, hantavirus and other emerging threats.

While advances in artificial intelligence, genomics, and molecular biology continue to accelerate the discovery of innovative vaccine and therapeutic candidates, biologics manufacturing remains a critical industry bottleneck. The ability to rapidly produce sufficient quantities of high-quality biologic therapies often determines how quickly they can reach patients.

Dyadic believes C1 is uniquely positioned to help address this challenge through a microbial, non-mammalian production platform engineered for speed, scalability, productivity, and manufacturing efficiency.

The global biologics market exceeds $690 billion and is projected to surpass $1.3 trillion by 2033. Monoclonal antibodies account for more than 65% of biologic sales, while recombinant proteins, vaccines, enzymes, and other biologics continue experience significant growth.

Dyadic believes the C1 platform can support multiple avenues for value creation across biologics manufacturing, recombinant protein, vaccine antigen, monoclonal antibody, therapeutic enzyme, and life sciences protein markets, representing an addressable opportunity of more than $25 billion.

The Company’s commercialization strategy is designed to progress from platform validation to revenue generation through partner-funded development programs, product sales, commercial manufacturing collaborations, platform and strain licensing, royalties, and broader adoption across life sciences and biopharmaceutical markets.

“Emerging outbreaks such as Ebola continue to remind us that discovery alone is not enough,” said Mark Emalfarb, Founder and Chief Executive Officer of Dyadic. “The real challenge is translating a genetic sequence or plasmid to high-quality product that can be developed and manufactured rapidly, affordably and at scale. Through our collaborations with organizations such as Scripps Research, CEPI, Fondazione Biotecnopolo di Siena, the Gates Foundation, and the European Vaccines Hub, we believe C1 is increasingly demonstrating its value as a faster, more flexible, and potentially lower-cost platform for biologics manufacturing, outbreak preparedness, and commercial applications.”

Dyadic Applied BioSolutions is a global biotechnology company that aims to develop and commercialize scalable, non-animal protein production platforms to meet growing global demand across the life sciences, food and nutrition, and bio-industrial markets. These high-value proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s proprietary Dapibus™ and C1 expression systems support rapid, cost-effective, and flexible manufacturing.

For more information, please visit http://www.dyadic.com.